To study the significance of mirna 23 b as a marker for neonatal sepsis.

Abstract

INTRODUCTION A systemic inflammatory response to infection in newborns, especially those born within the first 28 days of life, is known as neonatal sepsis, a potentially fatal clinical disease. It is a major cause of morbidity and mortality worldwide, particularly in areas with little resources, where healthcare systems struggle to detect it early and treat patients effectively1. Neonatal sepsis is divided into two categories: early onset sepsis (EOS) and late onset sepsis (LOS). Due to their young immune systems' limited capacity to fight infections, newborns are especially vulnerable. Prematurity, low birth weight, prolonged membrane rupture, maternal illnesses, and invasive treatments in the neonatal intensive care unit (NICU) are risk factors for neonatal sepsis. Neonatal sepsis prevalence varies greatly throughout the world, with lower and middle-income nations reporting greater rates because of inadequate prenatal care and restricted access to medical interventions2. Sepsis is still a difficult problem despite improvements in neonatal care because of delayed diagnosis, antibiotic resistance, and the high prevalence of sequelae and long-term impairment such as neurodevelopment delays3. With an emphasis on its epidemiology, classification, pathophysiology, clinical presentation, diagnostic techniques, therapy, and preventative strategies, this paper attempts to offer a thorough overview on neonatal sepsis and effective management and prompt treatment.